August 15th 2025
Children with spinal muscular atrophy (SMA) showed motor function improvements after switching to onasemnogene abeparvovec following prior treatment with nusinersen or risdiplam in a real-world study.
February 28th 2025
FDA Approves Symdeko to Treat the Underlying Cause of Cystic Fibrosis
Study Finds Merkel Cell Carcinoma Incidence Has Increased Since 2000
FDA Approves First Radioactive Drug for Rare Type of GI Cancer
Cancer Gene Profiling Test Can Open Doors to New Targeted Therapies